Karyopharm Therapeutics (KPTI) Asset Utilization Ratio (2013 - 2025)

Karyopharm Therapeutics has reported Asset Utilization Ratio for 13 years, with the latest figure at 1.43 in Q4 2025.

• For the quarter ending Q4 2025, Asset Utilization Ratio rose 73.92% year-over-year to 1.43; the trailing twelve-month figure through Dec 2025 stood at 1.43 (up 73.92% YoY), and the FY2025 full-year result was 1.07, up 49.24% from the prior year.
• Asset Utilization Ratio for Q4 2025 stood at 1.43, up from 1.42 in the prior quarter.
• The five-year high for Asset Utilization Ratio was 1.43 in Q4 2025, with the low at 0.36 in Q2 2021.
• Historically, Asset Utilization Ratio has averaged 0.75 across 5 years, with a median of 0.72 in 2024.
• Annual changes were most pronounced in 2022 — Asset Utilization Ratio jumped 150.56% — and 2023, when it plunged 49.83%.
• Karyopharm Therapeutics' Asset Utilization Ratio stood at 0.75 in 2021, then slipped by 28.95% to 0.53 in 2022, then grew by 7.36% to 0.57 in 2023, then jumped by 43.44% to 0.82 in 2024, then jumped by 73.92% to 1.43 in 2025.
• The last three Asset Utilization Ratio figures came in at 1.43 (Q4 2025), 1.42 (Q3 2025), and 1.18 (Q2 2025), per Business Quant data.